Wang J, Zhao Y, Chen Z, Huang R
Front Pharmacol. 2025; 15():1451713.
PMID: 39845792
PMC: 11751046.
DOI: 10.3389/fphar.2024.1451713.
Wang S, Zhang R, Wang S, Guo Q, Yin D, Song Y
Front Pharmacol. 2024; 15:1309148.
PMID: 39534085
PMC: 11555396.
DOI: 10.3389/fphar.2024.1309148.
Akagi T, Hamano H, Miyamoto H, Takeda T, Zamami Y, Ohyama K
Eur J Clin Pharmacol. 2024; 81(1):129-137.
PMID: 39443366
DOI: 10.1007/s00228-024-03767-6.
Huo B, Shu L, Xiao J, Yin N, Ai M, Jia Y
Front Pharmacol. 2024; 15:1292163.
PMID: 39403147
PMC: 11471622.
DOI: 10.3389/fphar.2024.1292163.
Koshiishi T, Nishioka N, Yoshimoto K
Asian Pac J Cancer Prev. 2024; 25(7):2291-2295.
PMID: 39068560
PMC: 11480620.
DOI: 10.31557/APJCP.2024.25.7.2291.
Clinical drug interactions between linezolid and other antibiotics: For adverse drug event monitoring.
Shu L, Huo B, Yin N, Xie H, Erbu A, Ai M
Pharmacol Res Perspect. 2024; 12(4):e1236.
PMID: 39049495
PMC: 11269369.
DOI: 10.1002/prp2.1236.
Adverse events associated with eteplirsen: A disproportionality analysis using the 2016-2023 FAERS data.
Dai Z, Wang G, Zhang J, Zhao Q, Jiang L
Heliyon. 2024; 10(13):e33417.
PMID: 39027557
PMC: 11255655.
DOI: 10.1016/j.heliyon.2024.e33417.
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration.
Fusaroli M, Salvo F, Begaud B, Alshammari T, Bate A, Battini V
Drug Saf. 2024; 47(6):585-599.
PMID: 38713347
PMC: 11116264.
DOI: 10.1007/s40264-024-01423-7.
Timing Matters: A Machine Learning Method for the Prioritization of Drug-Drug Interactions Through Signal Detection in the FDA Adverse Event Reporting System and Their Relationship with Time of Co-exposure.
Battini V, Cocco M, Barbieri M, Powell G, Carnovale C, Clementi E
Drug Saf. 2024; 47(9):895-907.
PMID: 38687463
PMC: 11324675.
DOI: 10.1007/s40264-024-01430-8.
A simulation-based comparison of drug-drug interaction signal detection methods.
Jung D, Jung I
PLoS One. 2024; 19(4):e0300268.
PMID: 38630680
PMC: 11023586.
DOI: 10.1371/journal.pone.0300268.
A Comparison of Signals of Designated Medical Events and Non-designated Medical Events: Results from a Scoping Review.
Sartori D, Aronson J, Erlanson N, Noren G, Onakpoya I
Drug Saf. 2024; 47(5):475-485.
PMID: 38401041
PMC: 11018663.
DOI: 10.1007/s40264-024-01403-x.
Drug-drug interaction assessment based on a large-scale spontaneous reporting system for hepato- and renal-toxicity, and thrombocytopenia with concomitant low-dose methotrexate and analgesics use.
Honma T, Onda K, Masuyama K
BMC Pharmacol Toxicol. 2024; 25(1):13.
PMID: 38303016
PMC: 10832291.
DOI: 10.1186/s40360-024-00738-6.
Multivariate generalized mixed-effects models for screening multiple adverse drug reactions in spontaneous reporting systems.
Gosho M, Ishii R, Ohigashi T, Maruo K
Front Pharmacol. 2024; 15:1312803.
PMID: 38292936
PMC: 10824888.
DOI: 10.3389/fphar.2024.1312803.
A novel efficient drug repurposing framework through drug-disease association data integration using convolutional neural networks.
Amiri R, Razmara J, Parvizpour S, Izadkhah H
BMC Bioinformatics. 2023; 24(1):442.
PMID: 37993777
PMC: 10664633.
DOI: 10.1186/s12859-023-05572-x.
Levetiracetam Interaction with Direct Oral Anticoagulants: A Pharmacovigilance Study.
Abou Kaoud M, Nissan R, Segev A, Sabbag A, Orion D, Maor E
CNS Drugs. 2023; 37(12):1111-1121.
PMID: 37991705
DOI: 10.1007/s40263-023-01052-1.
The role of antipsychotics and other drugs on the development and progression of neuroleptic malignant syndrome.
Kyotani Y, Zhao J, Nakahira K, Yoshizumi M
Sci Rep. 2023; 13(1):18459.
PMID: 37891209
PMC: 10611799.
DOI: 10.1038/s41598-023-45783-z.
Exploring the impact of design criteria for reference sets on performance evaluation of signal detection algorithms: The case of drug-drug interactions.
Kontsioti E, Maskell S, Pirmohamed M
Pharmacoepidemiol Drug Saf. 2023; 32(8):832-844.
PMID: 36916014
PMC: 10947279.
DOI: 10.1002/pds.5609.
Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
Xia S, Gong H, Zhao Y, Guo L, Wang Y, Zhang B
Cancers (Basel). 2023; 15(1).
PMID: 36612235
PMC: 9818197.
DOI: 10.3390/cancers15010240.
Do antibody-drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study.
Xia S, Zhao Y, Guo L, Gong H, Wang Y, Ma R
Front Pharmacol. 2022; 13:967017.
PMID: 36467034
PMC: 9710632.
DOI: 10.3389/fphar.2022.967017.
Comment on: "A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)".
Noguchi Y
Drug Saf. 2022; 45(12):1551-1552.
PMID: 36223038
DOI: 10.1007/s40264-022-01240-w.